Baseline characteristics and demographics
The study was started on February 15, 2020, and completed on October 5, 2020. A total of 160 patients were randomized: 80 in the PL9643 group and 80 in the placebo group. A total of 156 patients (97.5%) completed the study: 79 (98.8%) in the PL9643 group and 77 (96.3%) in the placebo group. A total of 4 patients (2.5%) were discontinued from this study: 1 (1.3%) in the PL9643 group and 3 (3.8%) in the placebo group (The demographic and baseline characteristics of the entire enrolled population are shown in Patient Characteristics for the Overall Intent-to-Treat PopulationSD, standard deviation.